3 Dividend Stocks to Double Up on Right Now

A financial analysis identifies AbbVie, Chevron, and Pfizer as undervalued dividend stocks poised for future growth despite current headwinds. AbbVie, facing declining Humira sales, is projected for high-single-digit revenue CAGR driven by its new drug pipeline and offers a nearly 4% dividend. Chevron, navigating climate concerns, is expanding production and investing in renewables while providing a 4.1% dividend and planning significant share buybacks. Pfizer is offsetting post-COVID sales drops and a patent cliff with new product launches and strategic acquisitions expected to add $25 billion in annual revenue by 2030, supported by a 5.9% dividend yield. These companies are presented as compelling income investments with strong long-term prospects.

Analysis

The analysis highlights AbbVie (ABBV), Chevron (CVX), and Pfizer (PFE) as compelling dividend stocks, currently facing market skepticism but poised for significant future growth. AbbVie, despite declining Humira sales and a Q1 2024 EPS fall, anticipates a high-single-digit revenue compound annual growth rate (CAGR) through 2030, driven by the strong performance of Skyrizi, Rinvoq, and its oncology pipeline. The company offers a nearly 4% forward dividend yield and boasts 52 consecutive years of dividend increases.

Chevron is strategically navigating climate concerns by projecting upstream production growth through at least 2027, with a 12% year-over-year production increase in Q1. Concurrently, it is investing heavily in hydrogen, renewable fuels, and carbon capture technology, while maintaining a 4.1% dividend yield and planning $17.5 billion in annual share repurchases post-Hess acquisition approval. This dual approach aims to capitalize on both traditional energy demand and the energy transition.

Pfizer is addressing post-COVID vaccine sales declines and an impending patent cliff by projecting new products and indications to generate substantial additional revenue. Strategic acquisitions since 2022, including Arena, Biohaven, Global Blood Therapeutics, ReViral, and Seagen, are expected to add approximately $25 billion in new annual revenue by 2030. The company offers a robust forward dividend yield of over 5.9% and has reaffirmed its commitment to dividend maintenance and growth.

Key Decisions for Investors

• Investors should consider these three stocks for long-term income-oriented portfolios, given their attractive dividend yields and management's commitment to sustained dividend growth.
• Monitor AbbVie's and Pfizer's pipeline execution and integration of new acquisitions, as successful product launches and synergy realization are crucial for offsetting patent expirations and legacy drug revenue declines.
• Evaluate Chevron's capital allocation strategy between traditional energy expansion and renewable investments, alongside the impact of its substantial share repurchase program on shareholder value and overall market positioning.